TSE:4502Pharmaceuticals
What Takeda Pharmaceutical (TSE:4502)'s Phase 3 Win For Oral Psoriasis Drug Means For Shareholders
In mid-December 2025, Takeda reported positive topline data from two pivotal Phase 3 trials of its next‑generation oral TYK2 inhibitor zasocitinib in adults with moderate‑to‑severe plaque psoriasis, showing superiority to placebo and an active comparator on key skin‑clearance endpoints.
Because zasocitinib is a once‑daily oral pill that achieved high rates of near‑complete and complete skin clearance, it could reshape treatment options in plaque psoriasis if successfully approved.
We’ll now...